References
- HerschornSKaplanSASunFNtaniosFDo patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?Urology20148351023102924582119
- ValentiniFAMartiBGRobainGIdiopathic and neurogenic detrusor overactivity: do the different patterns have urodynamic characteristics related to gender or neurological condition?Int Braz J Urol201339566367024267109
- LinkCLSteersWDKusekJWMcKinlayJBThe association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health surveyJ Urol2011185395596321247604
- PatraPBPatraSSex differences in the physiology and pharmacology of the lower urinary tractCurr Urol20136417918824917740
- CoyneKSSextonCCVatsVThompsonCKoppZSMilsomINational community prevalence of overactive bladder in the United States stratified by sex and ageUrology20117751081108721256571
- IrwinDEMilsomIHunskaarSPopulation-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol20065061306131517049716
- IrwinDEAbramsPMilsomIKoppZReillyKEPIC Study GroupUnderstanding the elements of overactive bladder: questions raised by the EPIC studyBJU Int2008101111381138718336602
- StewartWFVan RooyenJBCundiffGWPrevalence and burden of overactive bladder in the United StatesWorld J Urol200320632733612811491
- MilsomIAbramsPCardozoLRobertsRGThüroffJWeinAJHow widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence studyBJU Int200187976076611412210
- SekidoNHinotsuSKawaiKShimazuiTAkazaHHow many uncomplicated male and female overactive bladder patients reveal detrusor over-activity during urodynamic study?Int J Urol200613101276127917010004
- TelokenCCaraverFWeberFAOveractive bladder: prevalence and implications in BrazilEur Urol20064961087109216497431
- TemmlCHeidlerSPonholzerAMadersbacherSPrevalence of the overactive bladder syndrome by applying the International Continence Society definitionEur Urol200548462262715964133
- NittiVWRosenbergSMitchesonDHHeWFakhouryAMartinNEUrodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstructionJ Urol201319041320132723727415
- LeeJYKimHWLeeSJKohJSSuhHJChancellorMBComparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladderBJU Int200494681782015476515
- KaplanSARoehrbornCGGongJSunFGuanZAdd-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptomsBJU Int2012109121831184021966995
- VuichoudCLoughlinKBenign prostatic hyperplasia: epidemiology, economics and evaluationCan J Urol201522suppl 11626497338
- ChappleCRHerschornSAbramsPWangJTBrodskyMGuanZEfficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentrationBJU Int201010691332133820497416
- AbramsPKaplanSDe KoningGansHJMillardRSafety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstructionJ Urol20061753 Pt 19991004 discussion 100416469601
- de NunzioCFrancoGRocchegianiAIoriFLeonardoCLaurentiCThe evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstructionJ Urol2003169253553912544303